课题基金 / 基金详情

Immuno-gene therapy by secreted gp96-Ig fusion protein

Immuno-gene therapy by secreted gp96-Ig fusion protein
分泌型 gp96-Ig 融合蛋白的免疫基因治疗
批准号:
13670584
负责人:
YAMAZAKI Koichi
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

YAMAZAKI Koichi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Gp96 has useful properties as tumor vaccine for the generation of CD8 CTL independent of MHC restriction. We have developed a secreted form of gp96-Ig (gp96-Ig) by deleting the endoplasmic reticulum retention signal, KDEL, and replacing it with the Fc portion of murine IgG_1. Tumor cells transfected with and overexpressing gp96-Ig were less tumorigenic, compared to wild type tumors. Immunization of mice with the murine lymphoma E.G7 transfected with gp96-Ig (E.G7-gp96-Ig), but not with irradiated E.G7, induced immunity to subsequent challenge with E.G7. Depletion studies showed that CD8^+ cells were required for E.G7-gp96-Ig rejection throughout induction phase and effector phase, but not CD4^+ cells or macrophages. In this study, we examined the immunotherapeutical potency by gp96-Ig gene-transfected tumor cells. E.G7 was established in C57BL/6 mice for three days. Daily injections, beginning on day 4, of gp96-Ig-transduced tumor cells suppressed tumor growth remarkably when compared … More to PBS treatment or to treatment with control tumors treatment with control tumors secreting gp96-Ig. Beginning vaccination on day 5 after tumor transplantation, successful therapy required a vaccination schedule of two daily injections of E.G7-gp96-lg. In a Jung tumor model. LLC, LLC-gp96-Ig vaccines were equally effective as gp96 purified from LLC cells and comparable to IL-12-transduced tumor cells (LLC/1L12). There were no synergistic effects by a 1:1 mixture of LLC-gp96-Ig and LLC/IL12, suggesting that the two vaccines may act through similar cellular mechanisms. CD4^+ T cells were not required for vaccines by gp96-Ig-transduced tumor cells. CD8^+ cytotoxic activities specific for wild type tumor cells were induced by vaccines with gp96-Ig-transduced tumor cells. Moreover, adoptively transferred, ovalbumin specific T-cell receptor (TCR) transgenic CD8^+ cells (OT-1) responded with clonal expansion to the immunization with EG7-gp96-Ig. Our data suggest that tumors secreting gp96-Ig may be useful as potent anti tumor vaccines. Less
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
Hommura F, Furuuchi K, Yamazaki K, Ogura S, Kinoshita I, Shimizu M, Moriuchi T, Katoh H, Nishimura M, Dosaka-Akita H: "Increased expression of β-catenin predicts better prognosis in nonsmall cell lung carcinoma"Cancer. 94. 752-758 (2002)
Hommura F、Furuuchi K、Yamazaki K、Ogura S、Kinoshita I、Shimizu M、Moriuchi T、Katoh H、Nishimura M、Dosaka-Akita H:“β-连环蛋白表达增加可预测非小细胞肺癌更好的预后”癌症。 94.752-758 (2002)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
山崎浩一: "Annual Review免疫2001"中外医学社編. 308-315 (2002)
Koichi Yamazaki:“免疫学年度评论 2001”,由 Chugai Igakusha 编辑 308-315 (2002)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Dosaka-Akita H, Kinoshita I, Yamazaki K, Izumi H, Itoh T, Katoh H, Nishimura M, Matsuo K, Yamada Y, Kohno K: "N-acetylgalactosaminy1 transferase-3 (GalNAc-T3) is a potential new marker for non-small cell lung cancers"Br J Cancer. 87. 751-755 (2002)
Dosaka-Akita H、Kinoshita I、Yamazaki K、Izumi H、Itoh T、Katoh H、Nishimura M、Matsuo K、Yamada Y、Kohno K:“N-乙酰半乳糖胺 1 转移酶 3 (GalNAc-T3) 是一种潜在的新标记物
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Dosaka-Akita H, Kinoshita I, Yamazaki K, Izumi H, Itoh T, Katoh H, Nishimura M, Matsuo K, Yamada Y, Kohno K: "N-acetylgalactosaminyl transferase-3 (GalNAc-T3) is a potential new marker for non-small cell lung cancers"Br J Cancer. 87. 751-755 (2002)
Dosaka-Akita H、Kinoshita I、Yamazaki K、Izumi H、Itoh T、Katoh H、Nishimura M、Matsuo K、Yamada Y、Kohno K:“N-乙酰半乳糖胺基转移酶 3 (GalNAc-T3) 是一种潜在的新标记物
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
12
    Empirical Research on Printing Place Estimation Method Based on Bibliographical Investigation of Western Historical Social Science Literature
    • 批准号:
      23330066
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $5.57万
    • 财政年份:
      2011
    • 负责人:
      YAMAZAKI Koichi
    • 依托单位:
    A study of graph width parameters
    • 批准号:
      21500004
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.25万
    • 财政年份:
      2009
    • 负责人:
      YAMAZAKI Koichi
    • 依托单位:
    Implementation and evaluation of graph approximation algorithms
    • 批准号:
      16500008
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.28万
    • 财政年份:
      2004
    • 负责人:
      YAMAZAKI Koichi
    • 依托单位:
    Cellular immunotherapy and immune-gene therapy by heat shock protein gp96 and dendritic cells
    • 批准号:
      15590789
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2003
    • 负责人:
      YAMAZAKI Koichi
    • 依托单位:
    国内基金
    海外基金
    胎盘来源热休克蛋白gp96-癌胚抗原复合物及其活化的DC/T细胞制剂治疗脑胶质瘤的研究
    • 批准号:
      2022J011317
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2022
    • 负责人:
      林成实
    • 依托单位:
    高剂量gp96诱导调节性T细胞及治疗红斑狼疮等自身免疫疾病研究
    • 批准号:
      81871297
    • 项目类别:
      面上项目
    • 资助金额:
      57.0万元
    • 批准年份:
      2018
    • 负责人:
      孟颂东
    • 依托单位:
    肝癌预防性疫苗设计及机制研究
    • 批准号:
      81672815
    • 项目类别:
      面上项目
    • 资助金额:
      60.0万元
    • 批准年份:
      2016
    • 负责人:
      孟颂东
    • 依托单位:
    gp96及其辅助分子伴侣PRAT4A帮助Toll样受体膜外区正确折叠的分子机制
    • 批准号:
      31600619
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2016
    • 负责人:
      杨贝
    • 依托单位: